Reader Comment Regarding “Drugs Associated With the Development of Palmoplantar Keratoderma: A Systematic Review”

Abstract

Get full access to this article

View all access options for this article.

References

Chanprapaph

Rutnin

Vachiramon

. Multikinase inhibitor-induced hand-foot skin reaction: a review of clinical presentation, pathogenesis, and management. Am J Clin Dermatol. 2016;17(4):387-402.doi:10.1007/s40257-016-0197-1

27221667

Curry

JL.

Torres-Cabala

CA.

Kim

et al. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol. 2014;53(3):376-384.doi:10.1111/ijd.12205

23879247

Boyd

KP.

Vincent

Andea

Conry

RM.

Hughey

. Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma. J Am Acad Dermatol. 2012;67(6):1375-1379.doi:10.1016/j.jaad.2012.06.045

22940405

Boussemart

Routier

Mateus

et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24(6):1691-1697.doi:10.1093/annonc/mdt015

23406731